Results 221 to 230 of about 11,459,182 (339)
Non‐small cell lung cancer targeted treatment is limited to a few known genetic alterations, with few alternatives in advanced treatment lines. To direct treatment decisions by drug sensitivity testing (DST), this study compared several methods for tumor cell isolation from malignant effusions, pointing to repeated CD45+ cell depletion for effective ...
Navit Mooshayef+10 more
wiley +1 more source
Targets and Gene Therapy of ALS (Part 1). [PDF]
Shiryaeva O+3 more
europepmc +1 more source
Immunotherapy / Gene therapy / AIDS and cancer
Jean-Luc Darilx+2 more
openalex +1 more source
BCL-6 Gene Mutations in Posttransplantation Lymphoproliferative Disorders Predict Response to Therapy and Clinical Outcome [PDF]
Ethel Cesarman+5 more
openalex +1 more source
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon+13 more
wiley +1 more source
Programmable Single-Stranded Circular Antisense Oligonucleotides for Multitarget Gene Therapy. [PDF]
Pan Y+11 more
europepmc +1 more source
Interferon-β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice [PDF]
Xiao-Qiang Qin+7 more
openalex +1 more source
Carcinoma‐associated fibroblasts (CAFs) in tumors influence cancer progression. We identified endoglin (ENG) as a key factor in TGF‐β signaling in myofibroblastic CAFs (myCAFs), linked to poor breast cancer outcomes. Inhibiting ENG on myCAFs suppressed the TGF‐β‐Smad2/3 pathway, reducing primary tumor growth and metastasis.
Shoki Okubo+11 more
wiley +1 more source
Customised virus-like particles: Opening a new chapter for clinical precision gene therapy. [PDF]
Zhu X, Zhang Q, Zhou X, Cai Y, Hong J.
europepmc +1 more source
Rolig, Peng, and colleagues have shed new light on how dual blockade of PD1 and LAG3 enhances antitumor immunity. They found that response to immunotherapy with anti‐PD1 + anti‐LAG3 was associated with reprogramming of canonically suppressive CD4+ regulatory T cells to an inflammatory state.
Tullia C. Bruno, Anthony R. Cillo
wiley +1 more source